Linked Life Data

17430707

Source:http://linkedlifedata.com/resource/pubmed/id/17430707

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2007-4-13
pubmed:abstractText
Despite advances in HIV treatment and the availability of 22 approved antiretroviral drugs, newer compounds are needed that are better tolerated, less toxic, more convenient, or have improved activity against drug-resistant viruses. In addition to newer agents in development in traditional antiretroviral classes (reverse transcriptase inhibitors, protease inhibitors), a number of compounds in newer mechanistic classes also are under development, including entry inhibitors, integrase inhibitors, and maturation inhibitors. This review focuses on some of the investigational antiretroviral compounds that have reached clinical development and that offer the most promise for treatment of HIV-infected individuals.
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:month
May
pubmed:issn
1523-3847
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
243-51
pubmed:year
2007
pubmed:articleTitle
New antiretroviral agents.
pubmed:affiliation
Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, Box 566, 525 East 68th Street, New York, NY 10021, USA.
pubmed:publicationType
Journal Article